BNP Paribas Financial Markets Reduces Stake in Celcuity, Inc. $CELC

BNP Paribas Financial Markets reduced its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 20.5% in the fourth quarter, Holdings Channel reports. The fund owned 142,203 shares of the company’s stock after selling 36,648 shares during the quarter. BNP Paribas Financial Markets’ holdings in Celcuity were worth $14,183,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Celcuity in the 4th quarter worth approximately $1,317,000. SBI Okasan Asset Management Co.Ltd. bought a new stake in shares of Celcuity in the fourth quarter valued at $660,000. Intech Investment Management LLC raised its stake in shares of Celcuity by 1.4% in the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock valued at $1,295,000 after buying an additional 183 shares during the period. Geode Capital Management LLC lifted its position in shares of Celcuity by 8.4% during the 4th quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after buying an additional 64,213 shares during the last quarter. Finally, Integrity Alliance LLC. purchased a new position in shares of Celcuity during the 4th quarter valued at $451,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Insider Buying and Selling at Celcuity

In related news, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 37,000 shares of company stock worth $5,111,950. Insiders own 13.33% of the company’s stock.

Celcuity Stock Performance

Celcuity stock opened at $88.28 on Monday. The firm’s 50 day simple moving average is $122.01 and its 200 day simple moving average is $111.52. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The firm has a market capitalization of $4.31 billion, a PE ratio of -22.64 and a beta of 0.10. Celcuity, Inc. has a 1-year low of $11.27 and a 1-year high of $151.02.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, analysts expect that Celcuity, Inc. will post -3.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CELC has been the subject of several recent research reports. Guggenheim reissued a “buy” rating on shares of Celcuity in a report on Wednesday. Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Citizens Jmp boosted their price target on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a research report on Monday, May 4th. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a report on Monday, May 4th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $152.09.

Key Headlines Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $145 price target on Celcuity, and its longer-term forecasts still imply meaningful profitability potential by 2028-2030.
• Neutral Sentiment: The company also announced an upsized $500 million convertible senior notes offering due 2032, which improves funding for development but also raises dilution concerns for shareholders. Celcuity Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
• Neutral Sentiment: Celcuity expanded its Phase 3 VIKTORIA-2 trial to include endocrine-sensitive breast cancer patients, a development that could broaden the market opportunity if the study continues to progress well. Celcuity Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates for Celcuity, including lower projections for FY2026, FY2027, FY2028, FY2029, and Q4 2026, signaling expectations for continued losses before eventual profitability.
• Negative Sentiment: Investor sentiment also appears to have been hurt by reports that Celcuity shares fell after trial results disappointed some investors, even though other coverage described the late-stage breast cancer data as potentially strong or “practice-changing.” ASCO26: Celcuity punished as trial disappoints investors

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.